A group of researchers from Germany have found that real-time audio bio-feedback improves stability in degenerative cerebellar ataxia. Read more
A recently published study has demonstrated that intensive home-based speech therapy can improve dysarthria (difficulty speaking) in autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS). Read more
The AMRC Impact Report highlights the concrete ways that medical research charities make a difference to people and society through the research they fund Read more
The 'New Modalities Ecosystem’, launched in 2018 by the Finnish pharmaceutical company Orion, aims to exploit Finnish expertise to deliver new treatments and technologies for rare diseases. Read more
A recent study investigating the effect of investigating the effect of physiotherapy on patients with spinocerebellar ataxia type 7 (SCA7) has found that it to significantly improve symptoms. Read more
Ataxia UK's Head of Research Julie Greenfield reports on the 2018 Euro-ataxia annual conference held in Frankfurt. Read more
The ongoing European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) study, part-funded by Ataxia UK has released a report evaluating the clinical variability in Friedreich’s ataxia (FA) symptoms. Read more
Experiments in the laboratory using skin cells taken from people with Friedreich’s ataxia have shown that these cells may be more susceptible to damage caused by certain sun rays. Read more
Ataxia UK has been talking with Minoryx therapeutics, a company focusing on developing new drugs for rare conditions, and we are delighted with this new trial being announced. Read more
We are delighted that on 20 February 2019 the Ataxia UK Medical Guidelines were published in the Orphanet Journal of Rare Diseases. Read more
A study has found that a rapid, non-invasive eye exam could potentially be used as a tool for assessing Friedreich's ataxia patients and as a biomarker in clinical trials. Read more
Experiments performed in mice and in cells taken from Friedreich's ataxia (FA) patients reveal a protein called 'GRP75' might be an effective future treatment approach. Read more
The results of the patient communications survey conducted at the 2018 Ataxia UK conference were presented in London by Ataxia UK partners Costello Medical. Read more
Study finds anti-viral drug leads to decrease in frataxin levels and may be a potential future candidate for treating Friedreich's ataxia (FA). Read more
Second trial investigating troriluzole in spinocerebellar ataxia announced by Biohaven pharmaceuticals to commence at the end of January. Read more
Results from a study conducted at the London Ataxia Centre have shown that 3 proteins which may represent new biomarkers in Friedreich's ataxia (FA). Read more
A potential therapy for Glucose transporter 1 deficiency syndrome (Glut1 DS) has produced negative results in phase 3 of its clinical trial. Read more
Results from MOXIe study reveal potential therapy for Friedreich's ataxia, omaveloxolone, is well tolerated. Read more
Ataxia UK, GoFAR, FARA US and FARA Australia are pleased to announce the date of 3rd International Ataxia Research Conference. Read more
UK researchers guaranteed funding until the end of 2020 from EU programmes even in the event of a no-deal Brexit. Read more